NMN for Diabetic Kidney Disease

NAD Augmentation in Diabetes Kidney Disease

Recruiting Phase 2 Interventional Study
Type2diabetes Diabetic Kidney Disease
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
30 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
156 (estimated)
Sponsor
Brigham and Women's Hospital · Other
Who this trial is looking for

This trial is looking for adults with type 2 diabetes and kidney issues. Participants will take either NMN or a placebo for a study on kidney health.

Are You a Good Fit for This Trial?
Must be taking ACE inhibitorARBSGLT2 inhibitor
Rules you out Type 1 diabetesGestational diabetes

You may be able to join if

  • I am 30 years or older
  • I have type 2 diabetes
  • I have high morning UACR levels
  • I use an ACE inhibitor or ARB or SGLT2 inhibitor if my UACR is high
  • My eGFR is above 25
  • My HbA1c is below 10%
  • I can speak English, Spanish, or Haitian Creole
  • I agree to provide written consent

You may not be able to join if

  • I have very high UACR levels
  • I have liver issues with AST or ALT levels high
  • My eGFR is below 25
  • I have had a major heart event in the last 3 months
  • I have a substance use disorder
  • I have serious mental health issues that affect participation
  • I have been hospitalized for an acute illness in the last 3 months
  • I have a history of severe allergic reactions to vitamin B3

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. A man or a postmenopausal woman (complete cessation of menses for one or more years and /or FSH \> 20 U/L), 30 years or older 2. Has type 1 or type 2 diabetes mellitus, as indicated by any of the following: 1. Self-report of type 1 or type 2 diabetes plus the use of a pre…
Contacts

Shalender Bhasin, MD

6175259150

sbhasin@bwh.harvard.edu

CONTACT

Nancy Latham, PhD

6179999195

nklatham@bwh.harvard.edu

CONTACT